CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
HMPL-004 +1 moredrug
Likely dose
HMPL-004 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00655733
NCT00655733Phase 2Completed
CompareCT.gov

Double-blind, Randomized, Multicenter, Placebo-controlled Phase II Study of Efficacy and Safety of HMPL-004 in Subjects With Active Moderate Crohn's Disease

Hutchison Medipharma Limited·interventional·Posted Apr 10, 2008·Updated Jan 2, 2020

In Brief

A Phase 2 clinical trial evaluating HMPL-004 and Placebo for Crohn's Disease. Completed, enrolled 101 participants.

Detailed Summary

A double blind, randomized, multi-center, placebo-controlled study to evaluate the efficacy and safety of HMPL-004 in patients with active moderate Crohn's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 10, 2008
Enrollment StartApr 1, 2006
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.2 years ago

Interventions

HMPL-004drug

HMPL-004 1200 mg/d

Placebodrug

Placebo 1200 mg/d